Arterial Thrombosis

Coag Conversation Part 3: VWF and ADAMTS13: Cardiovascular Diseases

Introducing The Many Faces of von Willebrand Factor or, von Willebrand Factor, ADAMTS13, Malignancy and Beyond Part 3: von Willebrand Factor and ADAMTS13; Thrombotic Mechanisms and Cardiovascular Diseases. This 30″ talk features George A. Fritsma, MS, MLS, proprietor of The Fritsma Factor, Your Interactive Hemostasis Resource, and Emmanual Favaloro, PhD, Principal Hospital Scientist at the […]

Arterial Thrombosis

Webinar: The Many Faces of VWF, Part 2: Tumor Progression

Fritsma Factor participants, we invite you to view the next installment of our video series “Coag Conversations:” Dr. E. J. Favaloro: The Many Faces of von Willebrand Factor; or Von Willebrand Factor, ADAMTS13, Malignancy, and Beyond Part 2: Von Willebrand Factor and ADAMTS13: Tumor Progression and Beyond, sponsored by BioMedica Diagnostics, Inc.

Thrombotic Microangiopathies Presentation Handout

Click for the handout for “von Willebrand Factor, Friend or Foe,” which George presented on Friday, April 21, and Friday, April 29, 2023.

Arterial Thrombosis

Webinar: The Many Faces of VWF Part 1: Von Willebrand Factor and Acquired von Willebrand Syndrome

Fritsma Factor participants, we invite you to view Part 1 of our video: series ‘Coag Conversations’ The Many Faces of von Willebrand Factor; or Von Willebrand Factor, ADAMTS13, Malignancy, and Beyond: Von Willebrand Factor and Acquired von Willebrand syndrome, A Kaleidoscope of Presentations.” This is the first of a three-part series sponsored by BioMedica Diagnostics of […]

Arterial Thrombosis

VWF: Friend or Foe

I [Geo] will present, “Von Willebrand Factor, Friend or Foe: MA, TTP, aHUS, STEC-HUS, MAHA, PLEX, TIC, ADAMTS13, VWF What Does it All Mean?” for the combined ASCLS-Alaska, -Washington, and -Oregon on Friday, April 21, 1–2 CDT, and again for ASCLS-North Dakota on Friday, April 28, 2–3 CDT. These presentations are virtual. Click here for […]

Spinal Cord Stroke

On February 26, 2023, a Fritsma Factor participant asked about a relative’s diagnosis of spinal cord stroke. Spinal cord stroke is rare, 0.3–1% of all strokes. I’ve attached a review article, Romi F, Naess H. Spinal cord infarction in clinical neurology: a review of characteristics and long-term prognosis in comparison to cerebral infarction. Eur Neurol. […]

Arterial Thrombosis

EC Markers in COVID19 Thromboinflammation

The devastating COVID19 pandemic has led medical researchers led by Brandon M. Henry, MD, Division of Nephrology and Hypertension, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA to identify and characterize the pathophysiology of a number of thromboinflammation-related endothelial secretions. Some important terms relatively new to medical laboratory science include ADAMTS13/VWFag ratio, NETosis, and cell-free […]

Arterial Thrombosis

February, 2022 QQ Response: Platelet Aggs

Thanks to our 57 FF participants for your responses to our February 2022 Quick Question. The question stem was: “What single agonist is your first choice to measure platelet response to aspirin?” ADP: 14% [8] TRAP: 2% [1] Collagen: 2% [1] Epinephrine: 28% [16] Arachidonic acid: 54% [31] Although this question is a poll, my […]

Arterial Thrombosis

COVID-19: VWF/ADAMTS13 Balance

Thanks to Brandon Michael Henry MD, Cincinnati Children’s Hospital Medical Center for drawing attention to his award-winning review, co-authored with Drs. Emmanuel Favaloro and Giuseppe Lippi, which details the relationship between von Willebrand factor and ADAMTS13 and applies the VWF/ADAMTS13 activity ratio to the thrombotic progression of the SARS-CoV2 infection. The authors review 67 primary […]

Arterial Thrombosis

Primary CVD Disease: Is Low Dose ASA Effective?

Thanks to Dean Willett, Precision BioLogic Inc, for pointing me to this October 12, 2021 US Preventive Services Task Force release, “Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication,” which recommends against daily low-dose aspirin as a means to reduce the risk of cardiovascular disease, ischemic stroke, and colorectal cancer regardless of age or comorbities. […]

Antiplatelet Therapy

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George holds faculty appointments with Rutgers University and Michigan State University, and is a member of the International Society on Thrombosis and Hemostasis, American Association of Clinical Chemists, and American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question